ArticleVirchows Archiv : an international journal of pathology2025
High expression of RHOF is an effective diagnostic marker and a potential prognostic indicator for primary mediastinal large B-cell lymphoma.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the overlap of histological and molecular features of primary mediastinal large B-cell lymphoma (PMBL) with other lymphomas and its low incidence, the diagnosis and prognostic assessment of PMBL pose certain challenges. This study included 51 PMBL and 375 diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) from the GEO database and 65 PMBL and 117 DLBCL-NOS from a single center. At the transcriptional and protein levels, RHOF expression in PMBL was significantly higher than in DLBCL-NOS (P < 0.001). ROC curve analysis suggested that high RHOF expression had a high discriminative diagnostic ability for PMBL and DLBCL-NOS (transcriptional level, AUC = 0.913-0.940; protein level, AUC = 0.878). Comparing RHOF with commonly used PMBL diagnostic markers CD23, CD30, and PD-L1, it was found that high RHOF expression is a more useful diagnostic marker for PMBL (AUC (RHOF) = 0.878 > AUC (CD23) = 0.818 > AUC (CD30) = 0.756 > AUC (PD-L1) = 0.590). The diagnostic model based on CD23, CD30, and RHOF exhibits higher sensitivity for the diagnosis of PMBL than any of the individual markers mentioned above. Concerning prognosis, high RHOF transcriptional expression was significantly associated with poorer overall survival (OS) in PMBL (P = 0.00037), while high RHOF protein expression was significantly associated with poorer OS and progression-free survival (PFS) in PMBL (P = 0.034; P = 0.034). This study indicates that high RHOF expression in PMBL is closely associated with the diagnosis, prognosis, and clinical pathological features of the disease. High RHOF expression demonstrates a superior diagnostic ability in distinguishing PMBL from DLBCL-NOS compared to existing markers. Furthermore, research on RHOF expression in PMBL holds promise for providing new targets and insights for prognosis assessment and treatment of PMBL.
Indexed as
Identifiers
39630231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.